Ardent Health, Inc. (NYSE:ARDT) Given Average Rating of “Hold” by Brokerages

Shares of Ardent Health, Inc. (NYSE:ARDT) have been assigned an average rating of “Hold” from the twelve brokerages that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $14.6667.

A number of research firms recently weighed in on ARDT. Mizuho dropped their price objective on shares of Ardent Health from $20.00 to $12.00 and set an “outperform” rating on the stock in a report on Thursday, December 18th. UBS Group lowered their target price on Ardent Health from $14.50 to $14.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Stephens reduced their price objective on Ardent Health from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Friday, November 14th. JPMorgan Chase & Co. reduced their target price on shares of Ardent Health from $15.00 to $12.00 and set a “neutral” rating for the company in a research note on Monday, November 24th. Finally, Guggenheim lowered their price target on Ardent Health from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th.

More Ardent Health News

Here are the key news stories impacting Ardent Health this week:

• Negative Sentiment: Hagens Berman says a class action was filed after Ardent disclosed roughly $90M of adverse receivables/reserves adjustments that triggered a mid‑November ~33% share plunge; the firm seeks to represent investors harmed during the identified class period. Ardent Health (ARDT) Facing Securities Class Action Amid Receivables and Reserves Issues Driving 33% Plunge – Hagens Berman
• Negative Sentiment: Rosen Law Firm has announced a class action covering purchases between July 18, 2024 and November 12, 2025 and is urging investors to seek counsel — the lead‑plaintiff motion deadline is March 9, 2026, a date that can accelerate litigation activity. ROSEN, A RESPECTED AND LEADING FIRM, Encourages Ardent Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDT
• Negative Sentiment: Multiple other plaintiff firms (Glancy Prongay & Murray, Levi & Korsinsky, Bleichmar Fonti & Auld, Kirby McInerney, Faruqi & Faruqi, Pomerantz, Bragar Eagel & Squire and others) have filed notices or are soliciting lead‑plaintiff motions, increasing the likelihood of consolidated litigation and higher legal costs. Deadline Alert: Ardent Health, Inc. (ARDT) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
• Negative Sentiment: Several reminder notices (including from BFA Law, Portnoy, ClaimsFiler and others) emphasize the March 9 deadline for lead plaintiff appointments — such timelines typically accelerate discovery, media attention, and potential settlement pressure. ARDT CLASS REMINDER: Ardent Health, Inc. Class Action Deadline March 9 – Investors Notified to Contact BFA Law about its Filed Lawsuit to Protect Your Rights

Institutional Investors Weigh In On Ardent Health

Institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC boosted its position in shares of Ardent Health by 990.6% during the 2nd quarter. CWM LLC now owns 2,203 shares of the company’s stock valued at $30,000 after acquiring an additional 2,001 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Ardent Health in the 3rd quarter worth approximately $61,000. KLP Kapitalforvaltning AS bought a new position in shares of Ardent Health during the 3rd quarter worth approximately $80,000. New York State Common Retirement Fund boosted its stake in Ardent Health by 121.4% in the 2nd quarter. New York State Common Retirement Fund now owns 6,200 shares of the company’s stock valued at $85,000 after buying an additional 3,400 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new stake in Ardent Health in the third quarter valued at $103,000.

Ardent Health Stock Performance

Ardent Health stock opened at $8.59 on Monday. The company has a market cap of $1.23 billion, a price-to-earnings ratio of 5.92, a price-to-earnings-growth ratio of 4.91 and a beta of 0.72. Ardent Health has a 12 month low of $8.28 and a 12 month high of $15.65. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.08 and a quick ratio of 1.95. The stock’s 50-day moving average is $9.18 and its 200-day moving average is $11.72.

Ardent Health (NYSE:ARDT) last posted its earnings results on Wednesday, November 12th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.10. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.55 billion. Ardent Health had a net margin of 3.24% and a return on equity of 19.02%. Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. Equities analysts anticipate that Ardent Health will post 1.23 earnings per share for the current year.

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.